- Home
- YOU vs PTGX Comparison
YOU vs PTGX Comparison
Compare YOU & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOU
- PTGX
- Stock Information
- Founded
- YOU 2010
- PTGX 2006
- Country
- YOU United States
- PTGX United States
- Employees
- YOU N/A
- PTGX N/A
- Industry
- YOU Computer Software: Prepackaged Software
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- YOU Technology
- PTGX Health Care
- Exchange
- YOU Nasdaq
- PTGX Nasdaq
- Market Cap
- YOU 3.5B
- PTGX 3.7B
- IPO Year
- YOU 2021
- PTGX 2016
- Fundamental
- Price
- YOU $36.92
- PTGX $59.22
- Analyst Decision
- YOU Buy
- PTGX Strong Buy
- Analyst Count
- YOU 6
- PTGX 9
- Target Price
- YOU $36.17
- PTGX $70.44
- AVG Volume (30 Days)
- YOU 1.6M
- PTGX 925.0K
- Earning Date
- YOU 11-06-2025
- PTGX 11-06-2025
- Dividend Yield
- YOU 2.09%
- PTGX N/A
- EPS Growth
- YOU 105.20
- PTGX N/A
- EPS
- YOU 1.59
- PTGX 0.80
- Revenue
- YOU $835,529,000.00
- PTGX $209,180,000.00
- Revenue This Year
- YOU $16.29
- PTGX N/A
- Revenue Next Year
- YOU $11.01
- PTGX $248.17
- P/E Ratio
- YOU $23.14
- PTGX $73.55
- Revenue Growth
- YOU 19.85
- PTGX N/A
- 52 Week Low
- YOU $21.67
- PTGX $33.31
- 52 Week High
- YOU $38.88
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- YOU 61.37
- PTGX 55.46
- Support Level
- YOU $33.72
- PTGX $57.90
- Resistance Level
- YOU $38.80
- PTGX $60.40
- Average True Range (ATR)
- YOU 1.17
- PTGX 2.52
- MACD
- YOU -0.06
- PTGX -0.11
- Stochastic Oscillator
- YOU 63.03
- PTGX 63.87
About YOU Clear Secure Inc.
Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.